Each autumn, millions of adults roll up their sleeves for a routine flu shot — and most do so simply to avoid a week of fever and fatigue. But a growing body of research suggests that annual influenza vaccination may carry a far more profound benefit: a meaningfully lower risk of developing Alzheimer’s disease.
The findings, drawn from studies involving hundreds of thousands of older adults, are prompting scientists to look more carefully at the intersection of the immune system, viral infections, and brain aging.
A Striking Association in Nearly 2 Million Adults
The most comprehensive evidence comes from a 2022 propensity-score–matched cohort study published in the Journal of Alzheimer’s Disease by Bukhbinder and colleagues. Analyzing a nationwide U.S. insurance database spanning a decade (2009–2019), researchers compared flu-vaccinated and unvaccinated adults aged 65 and older across 935,887 matched pairs.
The results were notable: just 5.1% of vaccinated individuals developed Alzheimer’s disease during the follow-up period, compared to 8.5% in the unvaccinated group. That translates to a relative risk of 0.60 — a roughly 40% lower risk of Alzheimer’s among those who received an influenza vaccine. The number needed to vaccinate to prevent one case of Alzheimer’s was approximately 29 — a remarkably low figure for a non-pharmacological intervention.
“Influenza vaccination is associated with reduced Alzheimer’s disease risk in a nationwide sample of U.S. adults aged 65 and older,” the authors concluded.
New Research Examines Dose Differences
Building on this earlier work, a 2026 study published in Neurology — the flagship journal of the American Academy of Neurology — is now examining whether the type and dosage of influenza vaccine matters. Specifically, researchers are comparing outcomes between standard-dose and high-dose formulations of inactivated influenza vaccines (IIVs), the latter designed to produce a stronger immune response in older adults whose immunity tends to wane with age.
The work underscores that this protective association is robust enough to warrant investigation of how to optimize it — moving the conversation from “does vaccination help?” to “how can we maximize its benefit?”
Multiple Systematic Reviews Confirm the Pattern
The association has also held up under rigorous meta-analytic scrutiny. A 2025 systematic review and meta-analysis published in Age and Ageing by Maggi and colleagues confirmed that influenza vaccination is linked to a reduction in dementia risk across multiple studies and populations. A parallel meta-analysis by Yang and colleagues, also published in Age and Ageing in July 2025, sought to address inconsistent earlier findings and further characterized the strength of this relationship.
Taken together, the weight of peer-reviewed evidence now supports a meaningful, reproducible association — though researchers are careful to note that observational data cannot definitively establish causation.
Why Would a Flu Shot Protect the Brain?
The biological mechanisms proposed to explain this association are multifaceted and still being investigated. Scientists have put forward several interconnected hypotheses:
1. Reducing Infectious Burden and Neuroinflammation
Chronic low-grade inflammation is a well-established driver of Alzheimer’s pathology. Viral infections — including influenza and neurotropic viruses like herpes zoster — can trigger pro-inflammatory immune cascades that, over time, may accelerate amyloid-beta deposition and tau tangles in the brain. By reducing the frequency and severity of influenza infections, vaccination may help dampen this inflammatory burden before it reaches the central nervous system.
2. Trained Immunity
Research suggests vaccines may confer benefits beyond their specific pathogen target through a process called trained immunity — epigenetic remodeling of innate immune cells that makes the immune system more adept at combating a range of threats, including those that may promote neurodegeneration. This mechanism may also help counteract immunosenescence and inflammaging, the age-related deterioration and hyperactivation of the immune system that contribute to chronic inflammation.
3. Antigenic Cross-Reactivity With Amyloid-Beta
Perhaps the most intriguing mechanism involves structural similarities between the influenza virus itself and a key Alzheimer’s protein. Studies have proposed potential antigenic cross-reactivity between the fusion domain of influenza hemagglutinin — a protein on the surface of the flu virus — and the C-terminus of amyloid-beta (Aβ1–42) monomers. In theory, an immune response trained to recognize the flu virus might also enhance clearance of amyloid-beta in the brain.
4. Enhanced Clearance of Alzheimer’s Pathology
More broadly, vaccine-induced immune modulation may improve the immune system’s ability to clear amyloid-beta plaques, resolve neuroinflammation driven by existing Alzheimer’s pathology, and reduce inflammatory damage to surrounding healthy brain tissue.
It’s Not Just the Flu Vaccine
Influenza vaccination is not the only immunization associated with reduced dementia risk. A 2025 meta-analysis in Age and Ageing found that herpes zoster (shingles) vaccination was associated with a relative risk of 0.76 for any dementia — a 24% risk reduction. Pneumococcal vaccination has also shown a similar protective pattern in observational research.
This broader pattern across multiple vaccines strengthens the case that the protective effect is not specific to the flu shot itself, but may reflect a general immune mechanism — supporting the trained immunity hypothesis and the idea that keeping the immune system actively engaged may protect aging brains.
What This Means — and What It Doesn’t
It bears emphasizing that these are observational associations. Healthier, more health-conscious individuals may be more likely to get vaccinated, which could partially account for the lower Alzheimer’s rates — a confounding factor researchers attempt to control for, but cannot fully eliminate. Randomized controlled trials would provide stronger evidence, but following hundreds of thousands of adults for decades to track dementia incidence is logistically and ethically complex.
Still, the scale of the data, the consistency across multiple independent studies, and the biological plausibility of the proposed mechanisms together make the association difficult to dismiss.
Annual flu vaccination is already recommended by health authorities worldwide for adults aged 65 and older based on its well-established benefits for respiratory health. The emerging evidence that it may also support cognitive health with aging adds another dimension to the conversation — and offers a compelling reason for those who are vaccine-hesitant to reconsider.
The Takeaway
A growing body of research suggests that getting an annual flu shot may do more than prevent a miserable week of illness. Studies indicate that regular influenza vaccination is associated with a meaningfully lower risk of Alzheimer’s disease in older adults, possibly through mechanisms involving neuroinflammation reduction, trained immunity, and enhanced clearance of Alzheimer’s-related proteins in the brain. While scientists continue to investigate the underlying biology, the evidence is consistent enough to add brain health to the already substantial list of reasons to get vaccinated each year.
Consult your healthcare provider about whether annual influenza vaccination — and the higher-dose formulations now available for older adults — is appropriate for you.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.